ACMA Home
About ACMA
About Us
ACMA Publications
Archives
 
ACMA Cancer Center
 
To Cancer Patients
Cancer Breakthrough
ACMA Prostate 
Cancer Treatment
ACMA Leukemia
Treatment
 
Cardiovascular System Diseases
Digestive System Diseases
Endocrine System Diseases
Geriatrics Diseases
Hematopoietic System Diseases
Immune System Diseases
Infectious Diseases
Reproductive System Diseases
Mental Diseases
Metabolic Diseases
Nervous System Diseases
Obstetrics and Gynecology System Diseases
Ophthalmology Diseases
Osteoarthropathy Diseases
Pediatric Diseases
Respiratory System Diseases
Urinary System Diseases
Contact Us
Letters from Patients
Frequently Asked Questions
ACMA Patient Group
ACMA Patient Association
Special Links
                         
                                                   
             
 
 
                         
 
 
 

Liver Failure Treatment

 

Liver failure is characterized by acute or chronic decrease and loss of liver functions resulting from any kinds of liver diseases or liver damages.  

Western Medicine lacks effective drugs for liver failure treatments. 

ACMA Treatment for Liver Failure

On March 3, 2004, ACMA received a liver failure patient who had been receiving Western Medicine treatments before visiting ACMA.  The Western Medicine treatments could not control the liver failure process and her liver enzymes continuously increased to dangerous high levels.   Her

ANA EIA                   Positive        (ref: negative)

Bilirubin, Direct         0.4         (ref: 0.0--0.3)

GGT                           141        (ref: 2-60)

AST                            670        (ref: 2-35)

ALT                            904        (ref: 2-40)

LD                              382        (ref: 100-250)

% Saturation              52          (ref: 15-50)

After nearly two months CHM treatments at ACMA, the patient's clinical conditions got significantly improved.  The patient's liver enzymes tested on April 24, 2004 were as follows:

GGT                           46        (ref: 2-60)

AST                            32        (ref: 2-35)

ALT                            50        (ref: 2-40)

The patient's condition continuously improved.  The liver enzymes tested on May 23, 2004 were as follows:

Bilirubin , Direct        0.1           (ref: 0.0-0.3)

AST                            27            (ref: 2-35)

ALT                            31            (ref: 2-40)

The patient's liver failure has been stopped and reversed by the CHM treatments at ACMA.  Her life has been saved by CHM treatments without doing liver transplant.

As of June 2006 when this case report was prepared, the patient's liver enzymes are still in the normal ranges.  The patient is very grateful to ACMA for saving her life by means of CHM.

Related links:

 
ACMA Treatment Center
ACMA Treatment Programs
ACMA Cancer Center
Frequently Asked Questions
Letters from Patients

 

Back to Top   

 

  

 
ACMA Home   |   ACMA Publications    |   About ACMA   |   About Us    |   Archives   |    Special Links   |   Contact Us
ACMA Patient Association   |    ACMA Patient Group       
 
Copyright © 2008 American Chinese Medicine Association (ACMA).  All rights reserved.